Form 8-K - Current report:
SEC Accession No. 0001493152-24-025435
Filing Date
2024-06-27
Accepted
2024-06-27 16:15:21
Documents
17
Period of Report
2024-06-21
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 54832
2 ex3-1.htm EX-3.1 12126
3 ex3-2.htm EX-3.2 10413
4 ex99-1.htm EX-99.1 20909
5 ex99-1_001.jpg GRAPHIC 8561
  Complete submission text file 0001493152-24-025435.txt   301049

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE dare-20240621.xsd EX-101.SCH 3033
7 XBRL LABEL FILE dare-20240621_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE dare-20240621_pre.xml EX-101.PRE 22371
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3775
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

EIN.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 241079454
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)